Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trabectedin by Pharma Mar for Soft Tissue Sarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Trabectedin by Pharma Mar for Chondrosarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Trabectedin by Pharma Mar for Osteosarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Trabectedin by Pharma Mar for Ovarian Cancer: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Trabectedin by Pharma Mar for Chondrosarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II...
Trabectedin by Pharma Mar for Osteosarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II...
Trabectedin by Pharma Mar for Round Cell Liposarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Round Cell Liposarcoma. According to GlobalData,...
Trabectedin by Pharma Mar for Myxoid Liposarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Myxoid Liposarcoma. According to GlobalData, Phase...
Trabectedin by Pharma Mar for Dedifferentiated Liposarcoma: Likelihood of Approval
Trabectedin is under clinical development by Pharma Mar and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase...
PM-54 by Pharma Mar for Epithelial Ovarian Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData,...
PM-54 by Pharma Mar for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to...
PM-54 by Pharma Mar for Esophageal Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
PM-54 by Pharma Mar for Non-Small Cell Lung Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PM-54 by Pharma Mar for Malignant Pleural Mesothelioma: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData,...
PM-54 by Pharma Mar for Fallopian Tube Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Fallopian Tube Cancer. According to GlobalData,...
PM-54 by Pharma Mar for Melanoma: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Melanoma. According to GlobalData, Phase I...
Lurbinectedin by Pharma Mar for Sarcomas: Likelihood of Approval
Lurbinectedin is under clinical development by Pharma Mar and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
PM-54 by Pharma Mar for Small-Cell Lung Cancer: Likelihood of Approval
PM-54 is under clinical development by Pharma Mar and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...
Ecubectedin by Pharma Mar for Small-Cell Lung Cancer: Likelihood of Approval
Ecubectedin is under clinical development by Pharma Mar and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pharma Mar's Ecubectedin?
Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Ductal Carcinoma. According to...